A shortage of Danish drugmaker Novo Nordisk (NYSE:NVO)’s popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, the U.S. Food and Drug Administration’s website showed on Friday.

The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly (NYSE:LLY)’s weight-loss and diabetes drugs.

All doses of Novo’s diabetes treatment Ozempic and weight-loss drug Wegovy were listed as available on the FDA’s website in October, but the treatments were not taken off the official shortage list.

The health regulator usually assesses if all back-orders have been filled for the drug before deciding on whether a shortage has been resolved.